Shots:
The CHMP has recommended marketing authorization for Junod and Yaxwer, biosimilars of Amgen’s Xgeva & Prolia (denosumab)
Denosumab is approved to treat postmenopausal osteoporosis, prevent bone complications from cancer metastases, and treat unresectable giant cell tumors of bone
Junod & Yaxwer are mAbs (IgG2) that block RANKL, preventing osteoclast activation
Ref: Gedeon Richter | Image: Gedeon Richter…
